News
and Media


Press Releases and Media
February 28, 2023 | Press Release
Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting
Data demonstrates the potential of ‘1104 as an allergen-agnostic therapeutic for the treatment of food allergy NEW ORLEANS, LA and CAMBRIDGE, England, February 28, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today …
February 6, 2023 | Press Release
Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy
NEW ORLEANS and LONDON, February 6, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy …
January 5, 2023 | Article
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease
Topline data anticipated in Q2 2023 NEW ORLEANS, LA and LONDON, UK, January 5, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it has completed enrollment and has fully randomized all …